128 related articles for article (PubMed ID: 34076502)
1.
Mousavi A; Sabouri A; Hassanzadeh Eskafi A; Alirahimi E; Kazemi-Lomedasht F; Ghaderi H; Behdani M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):113-117. PubMed ID: 34076502
[TBL] [Abstract][Full Text] [Related]
2.
Hosseininejad-Chafi M; Alirahimi E; Ramezani B; Oghalaie A; Sotoudeh N; Ghaderi H; Kazemi-Lomedasht F; Habibi-Anbouhi M; Moazzami R; Behdani M
Iran J Basic Med Sci; 2022 Jan; 25(1):27-31. PubMed ID: 35656448
[TBL] [Abstract][Full Text] [Related]
3. Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line.
Shajari S; Farajollahi MM; Behdani M; Tarighi P
Mol Biotechnol; 2022 Nov; 64(11):1218-1226. PubMed ID: 35478310
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities.
Hamamichi S; Fukuhara T; Hattori N
Toxins (Basel); 2020 Oct; 12(10):. PubMed ID: 33076544
[TBL] [Abstract][Full Text] [Related]
5. Diphtheria toxin-derived, anti-PD-1 immunotoxin, a potent and practical tool to selectively deplete PD-1
Zhang T; Dong S; Zhai Y; Naatz L; Zhou Z; Chen M
Protein Sci; 2023 Sep; 32(9):e4741. PubMed ID: 37515422
[TBL] [Abstract][Full Text] [Related]
6. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity.
Greenfield L; Johnson VG; Youle RJ
Science; 1987 Oct; 238(4826):536-9. PubMed ID: 3498987
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18.
Hamawy MM; Tsuchida M; Cho CS; Manthei ER; Fechner JH; Knechtle SJ
Transplantation; 2001 Aug; 72(3):496-503. PubMed ID: 11502982
[TBL] [Abstract][Full Text] [Related]
8. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
[TBL] [Abstract][Full Text] [Related]
9. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.
Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA
Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970
[TBL] [Abstract][Full Text] [Related]
10. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent.
Shafiee F; Rabbani M; Jahanian-Najafabadi A
J Microbiol Methods; 2016 Nov; 130():100-105. PubMed ID: 27609715
[TBL] [Abstract][Full Text] [Related]
11. Antibody internalization after cell surface antigen binding is critical for immunotoxin development.
Kuo SR; Alfano RW; Frankel AE; Liu JS
Bioconjug Chem; 2009 Oct; 20(10):1975-82. PubMed ID: 19785403
[TBL] [Abstract][Full Text] [Related]
12. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells.
Wenning LA; Yazdi PT; Murphy RM
Biotechnol Bioeng; 1998 Feb; 57(4):484-96. PubMed ID: 10099226
[TBL] [Abstract][Full Text] [Related]
14. Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19
Zheng Q; Wang Z; Zhang H; Huang Q; Madsen JC; Sachs DH; Huang CA; Wang Z
Mol Oncol; 2017 May; 11(5):584-594. PubMed ID: 28306193
[TBL] [Abstract][Full Text] [Related]
15. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.
Wang Z; Duran-Struuck R; Crepeau R; Matar A; Hanekamp I; Srinivasan S; Neville DM; Sachs DH; Huang CA
Bioconjug Chem; 2011 Oct; 22(10):2014-20. PubMed ID: 21866954
[TBL] [Abstract][Full Text] [Related]
16. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
Schmohl JU; Todhunter D; Taras E; Bachanova V; Vallera DA
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316610
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.
Woo JH; Lee YJ; Neville DM; Frankel AE
Methods Mol Biol; 2010; 651():157-75. PubMed ID: 20686966
[TBL] [Abstract][Full Text] [Related]
18. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion.
Thompson J; Stavrou S; Weetall M; Hexham JM; Digan ME; Wang Z; Woo JH; Yu Y; Mathias A; Liu YY; Ma S; Gordienko I; Lake P; Neville DM
Protein Eng; 2001 Dec; 14(12):1035-41. PubMed ID: 11809934
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of a novel fibroblast growth factor receptor targeted immunotoxin on a human ovarian teratocarcinoma cell line.
Zhang H; Zhang S; Zhuang H; Lu F
Cancer Biother Radiopharm; 2006 Aug; 21(4):321-32. PubMed ID: 16999598
[TBL] [Abstract][Full Text] [Related]
20. The effect of anti-CD3-immunotoxin on T lymphocyte function in vitro.
Meng G; Jiang Y; Hubbard W; Thomas JM
Transpl Immunol; 1998 Mar; 6(1):53-9. PubMed ID: 9640629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
